Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X

Publications

Single cell mutation profiling delineates clonal trajectories in myeloid malignancies


Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, Durruthy-Durruthy R, Bowman M, Famulare C, Patel MA, Mendez P, Ainali C, Demaree B, Delley CL, Abate AR, Manivannan M, Sahu S, Goldberg AD, Bolton KL, Zehir A, Rampal R, Carroll MP, Meyer SE, Viny AD, Levine RL.
Nature Oct 2020
Abstract

Myeloid malignancies, including acute myeloid leukaemia (AML), arise from the expansion of haematopoietic stem and progenitor cells that acquire somatic mutations. Bulk molecular profiling has suggested that mutations are acquired in a stepwise fashion: mutant genes with high variant allele frequencies appear early in leukaemogenesis, and mutations with lower variant allele frequencies are thought to be acquired later1-3. Although bulk sequencing can provide information about leukaemia biology and prognosis, it cannot distinguish which mutations occur in the same clone(s), accurately measure clonal complexity, or definitively elucidate the order of mutations. To delineate the clonal framework of myeloid malignancies, we performed single-cell mutational profiling on 146 samples from 123 patients. Here we show that AML is dominated by a small number of clones, which frequently harbour co-occurring mutations in epigenetic regulators. Conversely, mutations in signalling genes often occur more than once in distinct subclones, consistent with increasing clonal diversity. We mapped clonal trajectories for each sample and uncovered combinations of mutations that synergized to promote clonal expansion and dominance. Finally, we combined protein expression with mutational analysis to map somatic genotype and clonal architecture with immunophenotype. Our findings provide insights into the pathogenesis of myeloid transformation and how clonal complexity evolves with disease progression.

VIEW

Area

Heme

Institution Type

Academia

Indication / Modality

Myeloproliferative Neoplasms (MPN), Acute Myleoid Leukemia (AML)

Goal of Study

MRD, CHIP, Clonal Heterogeneity, Tumor Profiling, Disease Modeling

Key Genes

DNMT3A, TET2, NPM1, FLT3

PAD Project

No

Analytes Assessed

SNV, InDels, Extracellular Protein

Sample Storage

Fresh Frozen

Sample Prep

Whole Cells

Sample Type

Patient Material

Tissue / Organ

Bone Marrow Aspirates

Species

Human

Panel Used

Custom

Proof Point Demonstrated

Better than Bulk, Co-occurrence, Survival Curves, Clonality, Phylogeny, Multi-omics, Zygosity
REQUEST QUOTE